Bivalent rsv prefusion f protein vaccine
Bivalent rsv prefusion f protein vaccine has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Sep 1, 2025: “Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial”.
1 paper studies it1 findingUpdated
See all 1 papers on bivalent rsv prefusion f protein vaccine
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“All-cause cardiorespiratory hospitalization incidence was lower in the RSVpreF group compared with the control group”
- 1 lab in 1 country
- 1 of 1 finding with company ties
- Human trial1
Studies in people
1 study gave bivalent rsv prefusion f protein vaccine to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases cardiorespiratory hospitalization9.9% (95% CI, 0.3%-18.7%) | Randomized trial | 131,276 peopleBothaged 60 years or olderOlder adults | JAMA, Sep 1, 2025 |
What did studies of bivalent rsv prefusion f protein vaccine find?
1Studies of bivalent rsv prefusion f protein vaccine measured one outcome, cardiorespiratory hospitalization.
Cardiorespiratory hospitalization
downin humans1
1 study
Cardiorespiratory hospitalization
downin humans1
Bivalent rsv prefusion f protein vaccine decreases cardiorespiratory hospitalization in humans (9.9% (95% CI, 0.3%-18.7%)).
“All-cause cardiorespiratory hospitalization incidence was lower in the RSVpreF group compared with the control group”
Human trialn = 131,276
JAMA